{
    "nct_id": "NCT05553834",
    "official_title": "A Phase II Study of PCSK9 Inhibitor Alirocumab and PD-1 Inhibitor Cemiplimab in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung Cancer: TOP2201",
    "inclusion_criteria": "* Histologically documented recurrent and/or metastatic non-small cell lung cancer\n* Progression after prior PD-1 directed therapy (as monotherapy or in combination with chemotherapy and/or anti-CTLA4, or anti-VEGF agents) - defined as investigator assessed progression from prior treatment\n* If molecularly altered NSCLC including EGFR, ALK, ROS1, MET exon 14, RET, BRAF, NTRK, progression on prior targeted therapy is required\n* Measurable disease by RECIST 1.1\n* ECOG Performance Status 0 or 1\n* Signed written informed consent\n* Minimum of 4 weeks from any other experimental anti-cancer therapies or prior PD-1 treatment\n* Meet all the laboratory criteria per protocol\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with PCSK9 inhibitors\n* Cardiac issues including MI, uncontrolled arrhythmia, symptomatic angina pectoris, active ischemia, or cardiac failure not controlled by medications.\n* Uncontrolled diabetes mellitus, defined as HbA1c > 10\n* Major surgery less than 4 weeks prior to study enrollment\n* Another malignant condition diagnosed within 3 years of study enrollment\n* Intolerance to prior PD-1/L1 treatment including discontinuation for severe or recurrent severe toxicity (including myocarditis or other myocardiotoxity, encephalitis, colitis, diarrhea, pancreatitis, hypo/hyperthyroidism, hypopituitarism, adrenal insufficiency, rash, autonomic neuropathy, myasthenia gravis, Guillain-Barre, myositis/polymyositis, hepatitis, Type 1 Diabetes, thrombocytopenia) or developed an immune checkpoint blockade related immune adverse event that was refractory to steroids and required additional systemic immunosuppressive medication.\n* Known history of HIV seropositivity or known acquired immunodeficiency syndrome (AIDS)\n* Additional exclusion criterion as per listed in the protocol",
    "miscellaneous_criteria": ""
}